On this page

Gentamicin Sulfate

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Gentamicin Sulfate
Generic name
Gentamicin Sulfate
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Cosette Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
4
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Gentamicin Sulfate 1 mg/g 1870650 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064056
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 29, 1994
Sponsor
COSETTE PHARMS NC
Products on application
1
Submissions recorded
1
Products approved under application 064056.
Product Trade name Form Strength Ingredient Status TE Flags
064056-001 GENTAMICIN SULFATE CREAM GENTAMICIN SULFATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064056.
Type No. Action Status Date Review
Original application 1 Approved April 29, 1994 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20231122). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20231122 HUMAN PRESCRIPTION DRUG · 20230131

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial superinfections of fungal or viral infections. Please Note: Gentamicin Sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. It is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with Gentamicin Sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Cream USP, 0.1% is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. Gentamicin sulfate ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. If a water-washable preparation is desired, the cream is preferable. Gentamicin Sulfate Cream USP, 0.1% has been used successfully in infants over one year of age, as well as in adults and children.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION A small amount of Gentamicin Sulfate Cream USP, 0.1% should be applied gently to lesions three or four times a day. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of Gentamicin Sulfate Cream USP, 0.1% to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to Gentamicin Sulfate under gelatin packing.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In patients with dermatoses treated with gentamicin sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with gentamicin sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of gentamicin sulfate followed by exposure to ultraviolet radiation. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Gentamicin Sulfate Cream USP, 0.1% is a wide spectrum antibiotic preparation for topical administration. Each gram of Gentamicin Sulfate Cream USP, 0.1% contains Gentamicin Sulfate USP equivalent to 1 mg of gentamicin base in a cream base of isopropyl myristate, propylene glycol, propylene glycol monostearate, polysorbate 40, purified water, sorbitol solution, and stearic acid, with methylparaben and butylparaben as preservatives.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Gentamicin Sulfate Cream, USP 0.1% is supplied in 15 gram tubes (0713-0683-15) and 30 gram tubes (0713-0683-31). Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Rev. 05/2022 8-0683CPLNC2 VC7632

Adverse event reports

Source: openFDA FAERS
15,708
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: GENTAMICIN SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0713-0683-15 0713-0683 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0683-15) / 15 g in 1 TUBE November 11, 2016
0713-0683-31 0713-0683 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0683-31) / 30 g in 1 TUBE November 11, 2016
45802-056-11 45802-056 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-056-11) / 30 g in 1 TUBE August 23, 2006
45802-056-35 45802-056 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-056-35) / 15 g in 1 TUBE December 5, 2006
0713-0683 0713-0683 Cosette Pharmaceuticals, Inc. — November 11, 2016
45802-056 45802-056 Padagis Israel Pharmaceuticals Ltd — August 23, 2006

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.